Memantin

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Memantin
(IUPAC) ime
3,5-dimetiltriciklo[3.3.1.13,7]dekan-1amin
ili
3,5-dimetiladamantan-1-amin
Klinički podaci
Robne marke Namenda
AHFS/Drugs.com Monografija
MedlinePlus a604006
Identifikatori
CAS broj 19982-08-2
ATC kod N06DX01
PubChem[1][2] 4054
DrugBank DB01043
ChemSpider[3] 3914
UNII W8O17SJF3T YesY
KEGG[4] D08174 YesY
ChEMBL[5] CHEMBL807 YesY
Hemijski podaci
Formula C12H21N 
Mol. masa 179,3 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Bioraspoloživost ~100%
Metabolizam Hepatički (<10%)
Poluvreme eliminacije 60–100 sati
Izlučivanje Renalno
Farmakoinformacioni podaci
Licenca

EU EMEA:linkUS FDA:link

Trudnoća ?
Pravni status S4 (Au), POM (UK), ℞-only (U.S.)
Način primene Oralno

Memantin je lek iz adamantanske klase lekova za tretiranje Alchajmerove bolesti| koji deluje na glutamatergični sistem putem blokiranja NMDA glutamatnih receptora. On je prvi put sintetisan u kompaniji Eli Lili 1968. Memantin je u prodaju pod imenima Aksura, Akatinol, Namenda, Ebiksa, Abiksa i Memoks. Uprkos dugogodišnjeg istraživanja, postoji malo dokaza da ima uticaja na blagu do umerene Alchajmerovu bolest.[6]

Reference[uredi - уреди | uredi kôd]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0061%28200004%2917:1%3C48::AID-YEA2%3E3.0.CO;2-H/full. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. Schneider, LS; Dagerman, KS, Higgins, JP, McShane, R (2011). „Lack of evidence for the efficacy of memantine in mild Alzheimer disease.”. Archives of neurology 68 (8): 991–8. PMID 21482915. 

Literatura[uredi - уреди | uredi kôd]

  • Lipton SA (2005). „The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism”. Current Alzheimer research 2 (2): 155–65. DOI:10.2174/1567205053585846. PMID 15974913. 

Vidi još[uredi - уреди | uredi kôd]

Spoljašnje veze[uredi - уреди | uredi kôd]